Several mechanisms of PARPi resistance have been identified in vitro (e.g. cancer cell lines and patient-derived organoids) and in vivo (clinical samples) with significant differences based on genetic background (e.g. BRCA1 vs. BRCA2 mutant) and tumor types (e.g. breast vs. ovarian cancer). This evidence concerns the gene BRCA1 and ovarian carcinoma.